[1] Korbonits M, Kaltsas G, Perry LA, Putignano P, Grossman AB, Besser GM, Trainer PJ. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab. 1999 Jul;84(7):2489-95.
[2] H. McDonald, J. Peart, N.D. Kurniawan, G. Galloway, S.G. Royce, C.S. Samuel, C. Chen, Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion,Biomedicine & Pharmacotherapy, Volume 127, 2020, 110165.
[3] McDonald H, Peart J, Kurniawan N, Galloway G, Royce S, Samuel CS, Chen C. Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Physiol Rep. 2018 May;6(9):e13699.
[4] Rahim A, O’Neill P, Shalet SM. The effect of body composition on hexarelin-induced growth hormone release in normal elderly subjects. Clin Endocrinol (Oxf). 1998 Nov;49(5):659-64.
[5] Zambelli V, Rizzi L, Delvecchio P, Bresciani E, Rezoagli E, Molteni L, Meanti R, Cuttin MS, Bovo G, Coco S, Omeljaniuk RJ, Locatelli V, Bellani G, Torsello A. Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Drug Target Insights. 2021 Nov 27;15:26-33.
[6] Maghnie M, Spica-Russotto V, Cappa M, Autelli M, Tinelli C, Civolani P, Deghenghi R, Severi F, Loche S. The growth hormone response to hexarelin in patients with different hypothalamic-pituitary abnormalities. J Clin Endocrinol Metab. 1998 Nov;83(11):3886-9.